Skip to content

Effect of an Oral Probiotic Tablet on Oral Bacteria and Clinical Measurements (ProBiora3)

ProBiora3 Oral Care Probiotics Usage

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01520974
Enrollment
48
Registered
2012-01-30
Start date
2012-01-31
Completion date
Unknown
Last updated
2012-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Health

Brief summary

The purpose of this study is to determine if an oral probiotic tablet taken once a day for twelve weeks can decrease the numbers of bacteria that are associated with tooth decay and gum disease in a dentally healthy, young adult population.

Detailed description

There are over 500 types of bacteria in the mouth. Most of these bacteria do not cause disease. However, some mouth bacteria can cause tooth decay and gum disease. The purpose of a probiotic tablet for the mouth is to put known healthy bacteria in the mouth. This study will compare the effect of the probiotic tablet on the levels of harmful or disease causing bacteria in the mouth to a placebo tablet that does not contain any probiotic bacteria.

Interventions

OTHERProBiora3 mints

Probiotic mint tablet taken once daily for 12 weeks containing ProBiora3, a combination of three known healthy bacteria

OTHERPlacebo tablet

Mint tablet taken once daily for 12 weeks without the ProBiora3 combination of three known healthy bacteria

Sponsors

University of Washington
CollaboratorOTHER
Oragenics, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* minimum of 20 teeth, with only a few fillings * good general health * willing to use an appropriate method of birth control during the study * measurable levels of Streptococcus mutans and one or more of the selected periodontal pathogens

Exclusion criteria

* chronic or acute illness such as heart disease, diabetes, cancer, hepatitis (liver disease) or HIV positive * radiation therapy or systemic cancer treatment (chemotherapy) * require antibiotics for dental treatment * pregnant or planning to become pregnant during the study period

Design outcomes

Primary

MeasureTime frameDescription
Enumeration of S. mutans in saliva and seven periodontal pathogens in subgingival plaque12 weeksQuantitative RT-PCR analyses for S. mutans in saliva, and A. actinomycetemcomitans, P. intermedia, T. forsythia, F. nucleatum, C. rectus, and E. corrodens in subgingival dental plaque.

Secondary

MeasureTime frameDescription
Breath odor12 weeksHalimeter used to evaluate breath odor
Teeth whiteness12 weeksTeeth whiteness measured with VITA Toothguide 3D-MASTER

Countries

United States

Contacts

Primary ContactMarilynn Rothen, RDH, MS
rothen@uw.edu206-685-8132
Backup ContactMary K Hagstrom, CDA
mkh8@uw.edu206-685-8132

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026